Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefotiam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.96 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.57 |
| ▸ | PGR | P06401 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 3/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 3/20 | 0.50 |
| ▸ | SLC22A11 | Q9NSA0 | 3/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefotiam SCHEMBL149538 | 0.99 | TDP1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 | |
| Cefotiam SCHEMBL11095123 | 0.99 | TDP1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 | |
| Cefotiam SCHEMBL16473046 | 0.99 | TDP1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 | |
| Cefotiam SCHEMBL9754124 | 0.99 | TDP1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 | |
| Cefotiam SCHEMBL9754126 | 0.99 | TDP1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 | |
| Cefotiam SCHEMBL6019446 | 0.99 | TDP1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 | |
| Cefotiam SCHEMBL193845 | 0.98 | L3MBTL1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 | |
| Cefotiam SCHEMBL11065530 | 0.98 | L3MBTL1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 | |
| Cefotiam SCHEMBL65480 | 0.98 | L3MBTL1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 | |
| Cefotiam SCHEMBL10899868 | 0.98 | L3MBTL1 (1.00) | TDP1LMNAHSD17B10L3MBTL1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | PROCTER & GAMBLE (US) | 2025-12-18 | — | — | US | disclosed |
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2016-12-15 | — | — | US | disclosed |
| EP-2949212-A1 | USE OF OXYGEN ANTAGONISTS FOR EX VIVO PRESERVATION OF TISSUES OR ORGANS | Fred Hutchinson Cancer Research Center (US) | 2015-12-02 | — | — | EP | disclosed |
| US-9090631-B2 | Process for purifying cefotiam hydrochloride | HAINAN LINGKANG PHARMACEUTICAL CO., LTD. (CN) | 2015-07-28 | — | — | US | disclosed |
| US-20150164064-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER | 2015-06-18 | — | — | US | disclosed |
| US-8822535-B2 | Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2014-09-02 | — | — | US | disclosed |
| CN-1901795-B | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HUTCHINSON FRED CANCER RES | 2014-03-26 | — | — | CN | disclosed |
| US-20140011994-A1 | NOVEL PROCESS FOR PURIFYING CEFOTIAM HYDROCHLORIDE | HAINANLINGKANG PHARMACEUTICAL CO., LTD. (CN) | 2014-01-09 | — | — | US | disclosed |
| EP-1879599-B1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | HUTCHINSON FRED CANCER RES (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-11-08 | — | — | US | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-1201665-B1 | PROCESS FOR THE PREPARATION OF BASIC ANTIBIOTIC-INORGANIC ACID ADDITION SALTS AND INTERMEDIATE OXALATES | EISAI CO LTD (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-6642377-B1 | Subjecting oxalate to salt exchange with alkali earth metal salt | EISAI CO., LTD. (JP) | 2003-11-04 | — | — | US | disclosed |
| EP-1201665-A1 | PROCESS FOR THE PREPARATION OF BASIC ANTIBIOTIC-INORGANIC ACID ADDITION SALTS AND INTERMEDIATE OXALATES | Eisai Co., Ltd. (JP) | 2002-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361356-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ENHANCING SURVIVABILITY OF CELLS, TISSUES, ORGANS, AND ORGANISMS | BCL2, BAX, HSF1 | TDP1 922/4885LMNA 318/4885HSD17B10 3687/4885 |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | TDP1 3344/4885LMNA 3777/4885HSD17B10 3276/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | TDP1 1116/4885LMNA 3148/4885HSD17B10 2858/4885 |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | HIF1A, HIF1AN, EGLN3 | TDP1 4659/4885LMNA 1858/4885HSD17B10 2135/4885 |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | PLAT, TBXA2R, THPO | TDP1 2119/4885LMNA 884/4885HSD17B10 4427/4885 |
| US-20140011994-A1 | NOVEL PROCESS FOR PURIFYING CEFOTIAM HYDROCHLORIDE | NOTUM, SAMM50, MGAM | TDP1 4551/4885LMNA 4335/4885HSD17B10 2803/4885 |
| US-20150164064-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | HSF1, HSP90AB1, HSP90AA1 | TDP1 1116/4885LMNA 3148/4885HSD17B10 2858/4885 |
| US-20250381110-A1 | SKIN CARE COMPOSITION AND METHOD OF USING THE SAME | SQSTM1, BECN1, CUTA | TDP1 488/4885LMNA 38/4885HSD17B10 3757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.